Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
…, B Vennapusa, H Zayed, S Lally, DK Strickland… - The Lancet …, 2017 - thelancet.com
Background Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed
against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and …
against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and …
Late effects of treatment in survivors of childhood acute myeloid leukemia
W Leung, MM Hudson, DK Strickland… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To investigate the incidence of and risk factors for late sequelae of treatment in
patients who survived for more than 10 years after the diagnosis of childhood acute myeloid …
patients who survived for more than 10 years after the diagnosis of childhood acute myeloid …
The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive …
…, S Kippenbrock, J Pope, J Carr, DK Strickland… - Blood, 2004 - ashpublications.org
Childhood cancer survivors transfused before 1992 are at risk for chronic hepatitis C (HCV)
infection. In 1995, St Jude Children's Research Hospital initiated an epidemiologic study of …
infection. In 1995, St Jude Children's Research Hospital initiated an epidemiologic study of …
Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature
BACKGROUND/PURPOSE:: Thyroid carcinomas can occur as a primary malignancy (PTM)
or secondary after another malignancy (STM). Information about the presentations and …
or secondary after another malignancy (STM). Information about the presentations and …
Hepatitis C infection among survivors of childhood cancer
DK Strickland, CA Riely, CC Patrick… - Blood, The Journal …, 2000 - ashpublications.org
Preliminary reports have suggested that survivors of childhood cancer and aplastic anemia
who are infected with the hepatitis C virus (HCV) have a low risk for progression to significant …
who are infected with the hepatitis C virus (HCV) have a low risk for progression to significant …
Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer
DK Strickland, JJ Jenkins… - Journal of pediatric …, 2001 - journals.lww.com
The results of preliminary reports of childhood cancer survivors with hepatitis C infection (HCV)
show that in none of these patients did the disease progress to liver failure or …
show that in none of these patients did the disease progress to liver failure or …
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6. 5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or …
…, ML Johnson, HA Burris, F Robert, DK Strickland… - 2016 - ascopubs.org
LBA8505 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT)
on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement …
on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement …
Cytotoxicity of α-Particle-emitting m-[211At]Astatobenzylguanidine on Human Neuroblastoma Cells
DK Strickland, G Vaidyanathan, MR Zalutsky - Cancer research, 1994 - AACR
Radioiodinated m-iodobenzylguanidine (MIBG) has been used with only limited success for
the treatment of neural crest tumors including neuroblastoma. Use of an MIBG analogue …
the treatment of neural crest tumors including neuroblastoma. Use of an MIBG analogue …
Meta‐[211AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agent
G Vaidyanathan, DK Strickland… - International journal of …, 1994 - Wiley Online Library
Meta‐[ 211 At]astatobenzylguanidine ([ 211 At]MABG) is an astatinated analogue of meta‐iodobenzylguanidine
(MIBG) that could be of value for therapeutic applications. The initial …
(MIBG) that could be of value for therapeutic applications. The initial …
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with …
…, HA Burris, D Spigel, F Meric-Bernstam, DK Strickland… - 2016 - ascopubs.org
653 Background: Next-generation sequencing often reveals potentially actionable molecular
alterations; however, data on approved targeted therapies in non-indicated tumors are …
alterations; however, data on approved targeted therapies in non-indicated tumors are …